Immuron Limited · ASX:IMC
Immuron — 25th Annual Dairy Industry Association of Australia Victorian State Conference (May 2010)
22 slides from Immuron's conference presentation, May 21, 2010
Slide 1: ASX Release: Presentation at Dairy conference by Immuron CEO
ASX Release 21 May 2010 For personal use only Presentation at Dairy conference by Immuron CEO: “Influenza prevention: Immunotherapy using Immuron Ltd polyclonal antibodies from cattle”. ABN 80 063 114 045 Corporate Details: st Melbourne and Sydney, Australia, 21 May, 2010. ASX Code: IMC Attached are
Slide 2: About Nycomed and About Immuron
About Nycomed: Nycomed is a privately owned pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Nycomed is one of th the top 25 global pharmaceutical companies and 16 in rank world-wide for co
Slide 3: Influenza prevention: Immunotherapy using polyclonal antibodies from cattle
For personal use only ASX:IMC Influenza prevention: Immunotherapy using polyclonal antibodies from cattle Dr Grant Rawlin, CEO www.immuron.com April 2010
Slide 4: For personal use only
IMmMUreNn Hadassah Medical Centre Metabolic Syndrome Influenza ImmMUren
Slide 5: Executive Summary
Executive Summary For personal use only Immuron is a publicly listed biopharmaceutical company based in Melbourne, Australia. Immuron has already developed and commercialised large scale antibody technology which enables production of tonnes of targeted antibodies used in the treatment and preve
Slide 6: Immuron: what do we do best?
Immuron: what do we do best? For personal use only Tonnes of targeted polyclonal antibodies that can be used on mucosal surfaces to treat diseases. o Proprietary registered veterinary vaccines are used to generate highly targeted antibody levels in dairy cattle colostrum (first milk). Approximately
Slide 7: Immuron works with polyclonal antibodies not monoclonals. Why?
Immuron works with Polyclonal antibodies not monoclonals. Why? For personal use only Polyclonals attach to many parts of their designated target eg bacteria, virus etc. Monoclonals only bind to one part of the designated target. Monoclonals are normally developed by Pharmaceutical companies for
Slide 8: Cost benefit of Immuron antibody
Cost benefit of Immuron antibody that allows antibody to be used differently For personal use only Monoclonal Antibody $50,000 / g in gram amounts for injection. (Pharmaceutical) Polyclonal serum $1,000 / g in gram amounts for injection (Pharmaceutical) Polyclonal Immuron $1 / g in tonne amoun
Slide 9: Can you make enough?
Can you make enough? For personal use only Travelan product is manufacturing proof in principle. Sold in Australia/New Zealand (Nycomed) Sold in South Africa (Pharmaco) Licensed for sale in USA (Alaven Pharma) Approved for sale in Turkey Up to 3 tonnes per season have been made to GMP st
Slide 10: The applications now
The applications now For personal use only Infectious diseases Travellers diarrhoea E. coli. Influenza (animal trials successful: combination of Melbourne and Hadassah work). C. difficile (laboratory trials and pilot human study successful) Oral immune modulation (Hadassah technology) Fa
Slide 11: Influenza Prevention: an OTC product
Influenza Prevention: an OTC product For personal use only Envisaged as an Over-The-Counter preventative product although the approach works with treatment as well. Work continuing at Melbourne University (Prof. Brown) and at Hadassah (Profs Ilan and Wolf) on a nasal spray product Overall glob
Slide 12: Successful Prevention from influenza infection in mouse models
Successful Prevention from influenza infection in mouse models For personal use only Groups of 5 mice were treated intranasally with 1mg of immune or non-immune IgG or immune F(ab)’2 fragments (Note: later experiments at 0.2 mg dose showed similar protection results) 1,2, 3 or 7 days later mice
Slide 13: Preventing infection up to days
Preventing infection up to 7 days For personal use only
Slide 14: Successful Treatment of existing influenza infections in a lethal mouse model
Successful Treatment of existing influenza infections in a lethal mouse model For personal use only Groups of 5 mice were infected with a lethal dose of PR8 H1N1 as a total respiratory tract infection and 24 hrs later the mice were treated intranasally with 1mg of immune or non-immune IgG or F (ab
Slide 15: Successful Treatment of existing influenza infections in a lethal mouse model
Successful Treatment of existing influenza infections in a lethal mouse model For personal use only
Slide 16: Dose definition and on to humans
Dose definition and on to humans For personal use only Up to 7 day protection has now been achieved at 0.2 mg per mouse. What about humans? … mice do not buy drugs… Now testing in the gold standard animal model at CSIRO (accepted as a direct parallel for challenge in humans)
Slide 17: Lets ask The Ferret!
For personal use only Lets ask The Ferret!
Slide 18: Ferret testing: Protection experiments
Ferret testing: Protection experiments For personal use only Linking to successful mouse work Define dose rate for larger animal Use other H1N1 variants eg New Caledonia (current circulating strain) Investigate dosing methods
Slide 19: Where to from there?
Where to from there? For personal use only Continue investigating beneficial effects on cell-mediated immune system. (Hadassah Medical Center) Just how does it protect for up to 7 days? Formulation/delivery development Safety/physiology trial in humans Already approved at Hadassah Medical
Slide 20: Main Research Partners on Influenza
Main Research Partners on Influenza For personal use only Hadassah Medical Centre, Jerusalem, Israel Major Hospital and Medical research centre in 2 campuses in Jerusalem. FDA compliant Clinical trials unit. Globally recognised medically research facility responsible for in excess of 50% of th
Slide 21: Commercialisation: Announced today
Commerialisation: Announced today For personal use only Nycomed and Immuron will collaborate to develop this technology with the aim of taking it to the global market. Nycomed is a Swiss-based Global Pharmaceutical company. 15th biggest in revenue in the world OTC market and top 25 overall pharm
Slide 22: Thank you
For personal use only Thank you Chagall windows Hadassah Medical Center, Jerusalem